Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press8610.17650/1726-9776-2012-8-1-77-81PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫTHE RATE AND SITE OF LYMPH NODE METASTASES DURING RADICAL PROSTATECTOMY AND EXTENDED LYMPHADENECTOMY IN PATIENTS WITH PROSTATE CANCERЧАСТОТА И ЛОКАЛИЗАЦИЯ МЕТАСТАЗОВ В ЛИМФАТИЧЕСКИХ УЗЛАХ ПРИ ВЫПОЛНЕНИИ РАДИКАЛЬНОЙ ПРОСТАТЭКТОМИИ И РАСШИРЕННОЙ ТАЗОВОЙ ЛИМФАДЕНЭКТОМИИ У БОЛЬНЫХ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫAlekseevB. Ya.АлексеевБ. Я.
Russian Federation
byalekseev@mail.ruNyushkoK. M.НюшкоК. М.
Russian Federation
byalekseev@mail.ruVorobyevN. V.ВоробьевН. В.
Russian Federation
byalekseev@mail.ruKalpinskiyA. S.КалпинскийА. С.
Russian Federation
byalekseev@mail.ruGolovashchenkoM. P.ГоловащенкоМ. П.
Russian Federation
byalekseev@mail.ruFrankG. A.ФранкГ. А.
Russian Federation
byalekseev@mail.ruAndreevaYu. Yu.АндрееваЮ. Ю.
Russian Federation
byalekseev@mail.ruP.A. Herzen Moscow Oncology Research InstituteМНИОИ им. П.А. Герцена300320128177812607201426072014https://oncourology.abvpress.ru/oncur/article/view/86

Prostate cancer (PC) is one of the most common male cancer diseases. Pelvic lymphadenectomy (PLAE) is an important diagnostic stage during both surgery and radiotherapy. The main goal of PLAE is to evaluate the pelvic lymph nodes (LN), which makes it possible to define the prognosis of the disease and to choose the most rational treatment policy. The paper analyzes the results of treating 298 moderate-to highrisk circumscribed and locally advanced PC patients undergoing prostatectomy or extended PLAE at the Department of Oncourology, P.A. Herzen Moscow Oncology Research Institute. The detection rate for LN metastases and their site are estimated and the risk for complications due to extended PLAE analyzed.

Рак предстательной железы (РПЖ) — одно из наиболее распространенных онкологических заболеваний у мужчин. Тазовая лимфаденэктомия (ТЛАЭ) является важным диагностическим этапом при выполнении как хирургического, так и лучевого лечения.

Основная цель ТЛАЭ заключается в оценке состояния тазовых лимфатических узлов (ЛУ), позволяющей определить прогноз заболевания и выбрать наиболее рациональную лечебную тактику. В статье представлен анализ результатов лечения 298 больных локализованным и местно-распространенным РПЖ группы промежуточного или высокого риска, которым выполнена радикальная простатэктомия и расширенная ТЛАЭ в отделении онкоурологии МНИОИ им. П.А. Герцена. Оценены частота выявления метастазов в ЛУ и их локализация, а также проанализирован риск развития осложнений при выполнении расширенной ТЛАЭ.

prostate cancerpelvic lymphadenectomylymph node metastasesрак предстательной железытазовая лимфаденэктомияметастазы в лимфатических узлах1. Состояние онкологической помощи населению России в 2010 году. Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2011.Состояние онкологической помощи населению России в 2010 году. Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2011.2. Матвеев Б.П. Клиническая онкоурология. М., 2011.Матвеев Б.П. Клиническая онкоурология. М., 2011.3. Walsh P.C., Jewett H.J. Radical surgery for prostatic cancer. Cancer 1980;45 (7 Suppl): 1906−11.Walsh P.C., Jewett H.J. Radical surgery for prostatic cancer. Cancer 1980;45 (7 Suppl): 1906−11.4. Wang L., Hricak H., Kattan M.W. et al. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol 2006; 186(3):743−8.Wang L., Hricak H., Kattan M.W. et al. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol 2006; 186(3):743−8.5. Briganti A., Chun F.K., Salonia A. et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 2006;49(6):1019−26.Briganti A., Chun F.K., Salonia A. et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 2006;49(6):1019−26.6. Heidenreich A., Von Klobloch R., Varga Z. et al. Extended pelvic lymphadenectomy in men undergoing radical retropubic prostatectomy (RRP) — an update on > 300 cases. J Urol 2004; 171:312 (A1183).Heidenreich A., Von Klobloch R., Varga Z. et al. Extended pelvic lymphadenectomy in men undergoing radical retropubic prostatectomy (RRP) — an update on > 300 cases. J Urol 2004; 171:312 (A1183).7. Weckermann D., Hamm M., Dorn R. et al. Sentinel lymph node dissection in prostate cancer. Experience after more than 800 interventions. Urologe A 2006;45(6):723−7.Weckermann D., Hamm M., Dorn R. et al. Sentinel lymph node dissection in prostate cancer. Experience after more than 800 interventions. Urologe A 2006;45(6):723−7.8. Malmstrom P.U. Lymph node staging in prostatic carcinoma revisited. Acta Oncol 2005; 44(6):593−8.Malmstrom P.U. Lymph node staging in prostatic carcinoma revisited. Acta Oncol 2005; 44(6):593−8.9. Joslyn S.A., Konety B.R. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006;68(1):121−5.Joslyn S.A., Konety B.R. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006;68(1):121−5.10. Allaf M.E., Palapattu G.S., Trock B.J. et al. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004;172(5 Pt 1):1840−4.Allaf M.E., Palapattu G.S., Trock B.J. et al. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004;172(5 Pt 1):1840−4.11. Steuber T., Budaus L., Walz J. et al. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int 2011;107(11):1755−61.Steuber T., Budaus L., Walz J. et al. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int 2011;107(11):1755−61.12. Schiavina R., Bertaccini A., Franceschelli A. et al. The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients. Anticancer Res 2010;30(6):2297−302.Schiavina R., Bertaccini A., Franceschelli A. et al. The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients. Anticancer Res 2010;30(6):2297−302.13. Schiavina R., Manferrari F., Garofalo M. et al. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediateand high-risk prostate cancer. BJU Int 2011;108(8):1262−8.Schiavina R., Manferrari F., Garofalo M. et al. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediateand high-risk prostate cancer. BJU Int 2011;108(8):1262−8.14. Weckermann D., Holl G., Dorn R. et al. Reliability of preoperative diagnostics and location of lymph node metastases in presumed unilateral prostate cancer. BJU Int 2007; 99(5):1036−40.Weckermann D., Holl G., Dorn R. et al. Reliability of preoperative diagnostics and location of lymph node metastases in presumed unilateral prostate cancer. BJU Int 2007; 99(5):1036−40.15. Briganti A., Blute M.L., Eastham J.H. et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009;55(6):1251−65.Briganti A., Blute M.L., Eastham J.H. et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009;55(6):1251−65.16. Heidenreich A., Von Klobloch R., Varga Z. et al. Extended pelvic lymphadenectomy in men undergoing radical retropubic prostatectomy (RRP) — an update on > 300 cases. J Urol 2004; 171:312.Heidenreich A., Von Klobloch R., Varga Z. et al. Extended pelvic lymphadenectomy in men undergoing radical retropubic prostatectomy (RRP) — an update on > 300 cases. J Urol 2004; 171:312.17. Tokuda Y., Carlino L.J., Gopalan A. et al. Prostate cancer topography and patterns of lymph node metastasis. Am J Surg Pathol 2010;34(12):1862−7.Tokuda Y., Carlino L.J., Gopalan A. et al. Prostate cancer topography and patterns of lymph node metastasis. Am J Surg Pathol 2010;34(12):1862−7.18. Briganti A., Chun F.K., Salonia A. et al. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol 2007; 51(1):112−9.Briganti A., Chun F.K., Salonia A. et al. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol 2007; 51(1):112−9.19. Vermeeren L., Meinhardt W., van der Poel H.G. et al. Lymphatic drainage from the treated versus untreated prostate: feasibility of sentinel node biopsy in recurrent cancer. Eur J Nucl Med Mol Imaging 2010;37(11):2021−6.Vermeeren L., Meinhardt W., van der Poel H.G. et al. Lymphatic drainage from the treated versus untreated prostate: feasibility of sentinel node biopsy in recurrent cancer. Eur J Nucl Med Mol Imaging 2010;37(11):2021−6.20. Hinev A., Klissarova A., Ghenev P. et al. Radioisotopic detection of sentinel lymph nodes in clinically localized high-risk prostate cancer. J BUON 2009;14(4):661−7.Hinev A., Klissarova A., Ghenev P. et al. Radioisotopic detection of sentinel lymph nodes in clinically localized high-risk prostate cancer. J BUON 2009;14(4):661−7.21. Clark T., Parekh D.J., Cookson M.S. et al.Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003;169(1):145−7.Clark T., Parekh D.J., Cookson M.S. et al.Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003;169(1):145−7.22. Burkhard F.C., Schumacher M.C., Studer U.E. An extended pelvic lymph-node dissection should be performed in most patients if radical prostatectomy is truly indicated. Nat Clin Pract Urol 2006;3(9):454−5.Burkhard F.C., Schumacher M.C., Studer U.E. An extended pelvic lymph-node dissection should be performed in most patients if radical prostatectomy is truly indicated. Nat Clin Pract Urol 2006;3(9):454−5.23. Thurairaja R., Studer U.E., Burkhard F.C. Indications, extent, and benefits of pelvic lymph node dissection for patients with bladder and prostate cancer. Oncologist 2009;14(1):40−51.Thurairaja R., Studer U.E., Burkhard F.C. Indications, extent, and benefits of pelvic lymph node dissection for patients with bladder and prostate cancer. Oncologist 2009;14(1):40−51.24. Eden C.G., Arora A., Rouse P. Extended vs standard pelvic lymphadenectomy during laparoscopic radical prostatectomy for intermediate- and high-risk prostate cancer. BJU Int 2010;106(4):537−42.Eden C.G., Arora A., Rouse P. Extended vs standard pelvic lymphadenectomy during laparoscopic radical prostatectomy for intermediate- and high-risk prostate cancer. BJU Int 2010;106(4):537−42.